By Sahithya K · Reviewed by Divya Chandradhara · Published 23 October 2026
Clinical drug development is conventionally divided into four phases. Phase I tests safety and tolerability when a drug is first given to humans, Phase II explores effectiveness and dose in patients, Phase III confirms benefit to support marketing approval and Phase IV studies the drug after approval. In India the phases are described in the First Schedule of the New Drugs and Clinical Trials Rules, 2019.
What clinical trial phases mean under ICH E8(R1) and the NDCT Rules
The phase labels describe the purpose of a study, not a fixed legal sequence. ICH E8(R1), General Considerations for Clinical Studies, adopted on 6 October 2021, says the phase concept “is a description and not a requirement” and that phases may overlap or be combined. It groups studies by objective instead: human pharmacology (usually phase 1), exploratory and confirmatory studies (usually phases 2 and 3) and post-approval studies (usually phase 4).
The Indian framework uses the same four phases. The gazette text of the NDCT Rules states in the First Schedule that clinical drug development “generally consists of four phases (Phase I-IV)” and then defines the objective of each.
Phase I clinical trials: safety and tolerability in the first human doses
Phase I estimates safety and tolerability when an investigational new drug is first given to humans. Under the First Schedule, Phase I studies usually have non-therapeutic objectives and may be conducted in healthy subjects or in certain types of patients. Drugs with significant potential toxicity, such as cytotoxic drugs, are usually studied in patients.
The First Schedule lists four objectives a Phase I study may serve, alone or in combination:
Maximum tolerated dose: the tolerability of the dose range expected in later studies and the nature of the adverse reactions to expect, using single and multiple doses.
Pharmacokinetics: how the drug is absorbed, distributed, metabolised and excreted.
Pharmacodynamics: the drug’s effects in relation to blood levels, in healthy volunteers or in patients with the target disease.
Early measurement of drug activity, as a secondary objective, where activity is readily measurable after short exposure.
The Rules add that Phase I should preferably be carried out by investigators trained in clinical pharmacology, with facilities to observe and monitor subjects closely. For first-in-human studies, the starting dose is calculated from the non-clinical pharmacology and toxicology data.
Phase II clinical trials: effectiveness and dose in patients
Phase II evaluates whether the drug is effective for a particular indication in patients with the condition, and identifies the common short-term side effects and risks. The First Schedule says Phase II studies use patients selected by relatively narrow criteria, giving a relatively homogeneous population, and that the studies should be closely monitored.
A central goal of Phase II is to determine the dose and regimen for Phase III. Doses used in Phase II are usually, though not always, lower than the highest doses used in Phase I. Phase II can also evaluate potential endpoints, treatment regimens and target populations, such as mild against severe disease, for the studies that follow.
Phase III clinical trials: confirming benefit for marketing approval
Phase III demonstrates or confirms therapeutic benefit. The First Schedule describes Phase III studies as designed to confirm the preliminary evidence from Phase II that a drug is safe and effective for the intended indication and population, and as intended to provide an adequate basis for marketing approval.
Phase III may also explore dose-response relationships and use of the drug in wider populations and at different stages of disease. It may also study the drug in combination with other drugs. For drugs intended for long-term use, studies of extended exposure are ordinarily conducted in Phase III. These studies complete the information needed for the prescribing information.
Phase IV clinical trials: post-marketing studies after approval
Phase IV trials are performed after a drug is approved and relate to the approved indication. The First Schedule says they go beyond the earlier demonstration of safety, efficacy and dose, and include additional drug-drug interaction, dose-response or safety studies as well as trials supporting use under the approved indication, such as mortality or morbidity studies and epidemiological studies.
A Phase IV trial in India still runs under an approved protocol with defined objectives and inclusion and exclusion criteria. The Fifth Schedule of the Rules applies the same ethical protections to it, including compensation for trial-related injury or death and good clinical practice guidelines. Phase IV sits alongside the wider post-marketing surveillance obligations that follow approval.
Phase I to Phase IV compared
Table 1. The four phases at a glance
| Phase | Primary objective | Who usually takes part | What it feeds into |
|---|---|---|---|
| I | Safety and tolerability on first administration; pharmacokinetics and pharmacodynamics | Healthy subjects, or patients where the drug carries significant potential toxicity | Dose range and safety profile for Phase II |
| II | Effectiveness for an indication; common short-term side effects; dose and regimen | Patients selected by relatively narrow criteria | Dose, regimen and endpoints for Phase III |
| III | Confirmation of therapeutic benefit and safety in the intended population | Wider patient populations, including long-term exposure where relevant | Marketing approval and prescribing information |
| IV | Further safety, interaction, dose-response and outcome evidence after approval | Patients under the approved conditions of use | Post-approval benefit-risk assessment |
Which clinical trial phases must be run in India
Where a new drug substance is discovered or developed in India, the Second Schedule requires clinical trials in India from Phase I onwards. Where the drug was discovered or developed outside India, Phase I data generated abroad is submitted with the application. The Central Licencing Authority may then permit a repeat of Phase I, or Phase II followed by Phase III conducted concurrently with the global trials for that drug.
For a drug introduced in India for the first time, a Phase III trial may be required in India before marketing permission is granted, unless it is exempted. For drugs already approved outside India, the First Schedule says Phase III studies in pharmaceutical development may be needed if scientifically and ethically justified, mainly to show efficacy and safety in Indian patients, and the Authority may first require pharmacokinetic studies. Where the local trial is waived, bioequivalence studies of the drug may be required instead, through BA/BE studies.
Approvals every phase needs in India before enrolment
The same permission conditions apply whatever the phase. A clinical trial of a new drug or investigational new drug needs permission from the Central Licencing Authority, applied for in Form CT-04, approval of the protocol by a registered Ethics Committee at each site and written informed consent from every trial subject. Under rule 25 the trial must be registered with the Clinical Trials Registry of India before the first trial subject is enrolled.
Safety reporting runs on the same clock in every phase. The investigator reports every serious adverse event within twenty-four hours of its occurrence, under rule 42. The detail of permissions, timelines and forms is set out in the NDCT Rules guide, and sponsors planning a programme across phases can discuss it with BioAgile’s clinical trial services team.
Questions about clinical trial phases
What are the four phases of clinical trials?
Phase I tests safety and tolerability when a drug is first given to humans. Phase II evaluates effectiveness and short-term side effects in patients and sets the dose for later studies. Phase III confirms benefit and safety to support marketing approval. Phase IV covers studies carried out after approval under the approved indication.
Are Phase I trials always done in healthy volunteers?
No. The First Schedule of the NDCT Rules says Phase I studies may be conducted in healthy subjects or certain types of patients. Drugs with significant potential toxicity, such as cytotoxic cancer drugs, are usually studied in patients, because exposing healthy volunteers to that toxicity would not be justified.
What is the difference between Phase II and Phase III?
Phase II explores whether the drug works for an indication and which dose and regimen to take forward, in a relatively narrow and homogeneous patient group. Phase III confirms the benefit and safety in the intended population, often a wider one, and provides the evidence base for marketing approval and prescribing information.
Is there a Phase 0 in India?
The NDCT Rules do not name a Phase 0. The First Schedule describes four phases, Phase I to Phase IV. Some development programmes run very early exploratory studies before conventional Phase I, but in India any clinical trial of an investigational new drug still needs permission from the Central Licencing Authority and Ethics Committee approval.
Do all phases have to be repeated in India?
Not always. A drug discovered or developed in India is tested in India from Phase I. For a drug developed elsewhere, Phase I data from abroad is submitted and the Central Licencing Authority decides what is needed next. A drug new to India may need a local Phase III trial unless exempted.
Do Phase IV trials need ethics committee approval and compensation cover?
Yes. Under the Fifth Schedule of the NDCT Rules, a Phase IV trial runs under an approved protocol, and the ethical protections for trial subjects apply in full. That includes compensation for trial-related injury or death and adherence to good clinical practice guidelines.
About this guide
This guide is based on the First, Second and Fifth Schedules of the New Drugs and Clinical Trials Rules, 2019, as published by the Central Drugs Standard Control Organisation, and on ICH E8(R1), General Considerations for Clinical Studies. It was written by Sahithya K, and reviewed by Divya Chandradhara It states the position as at 23 October 2026 and is reviewed every six months and after any amendment to the Rules.